MSTN and rheumatoid arthritis: Studies in mice show that inhibition of the myokine myostatin pathway leads to an increase in bone mass, whereas (161) myostatin reduces osteoclast formation and bone destruction in a TNF-α transgenic mouse model of rheumatoid arthritis (162).